2024 Annual General Meeting Presentation
Released
Released
Announcement PDF
At the forefront of microbiome
diagnostics & therapeutics
Annual General Meeting 2024
CEO’s Address & Trading Update
ASX: MAP
29 November 2024
Authorised for release by the CEO & Chair
Disclaimer
This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba).
Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any
obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in
evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act).
Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including
industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.
Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.
Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is
not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you
should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.
Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been
prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this
Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment
objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.
Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial
or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and
other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect",
"intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forwardlooking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking
statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of
Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results,
performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at
the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking
statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.
Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for
illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance.
Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in
this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.
Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or
damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency,
accuracy, reliability or completeness of this Presentation.
2
Trading Update
3
Trading update
1) Continued strong growth momentum for MetaXplore in Australia
-
Following record Australian MetaXplore sales in October, this strong growth momentum has continued into
November
With 5 weeks remaining, H1FY25 YTD MetaXplore sales are already ahead of H2FY24. Q2FY25 annualised run rate
of 11,000+ tests versus an annualised run rate of 7,238 in Q1FY25
2) MetaPanel sales continuing to build across all major states through the Sonic Healthcare (ASX: SHL)
network.
-
Milestone of 500+ MetaPanel tests sold since launch March-24
Continued MetaPanel clinical adoption growth, is expected to be accelerated by ongoing sales and marketing
activities as well as upcoming clinical utility study results and associated publications
3) United Kingdom: Invivo Clinical advancing into new growth phase
-
New sales team continue to build momentum with early access of MetaXplore
MetaXplore access commenced in Oct with first MetaXplore orders, samples received and reports delivered
Appointment of Alaster Stockwell-Jones as Commercial Director, ex Stryker, GE Healthcare & Eli Lilly
4
Trading Update - Australia
5
Australian MetaXplore sales growth momentum continues to accelerate
Q2FY25 annualised run-rate of 11,000+
11,000+
11,000
MetaXplore
Annualised Run Rate
Continued strong sales
growth momentum for
MetaXplore.
5,814
Q2FY25 YTD Annualised run
rate of 11,000+ MetaXplore
tests sold
3,564
1,910
H1FY23
H2FY23
H1FY24
H2FY24
H1FY25
YTD
H1FY25 YTD
Trading Update - Australia
6
Australian MetaXplore sales momentum continues to accelerate
3,500+ MetaXplore tests sold in H1FY25 YTD
MetaXplore Sales
Australia
3,500+
Continued strong sales
growth momentum for
MetaXplore.
2,935
1,841
With 5 weeks remaining,
H1FY25 YTD MetaXplore
sales are already ahead of
H2FY24. Q2FY25 annualised
run rate of 11,000+ tests
versus 7,238 in Q1FY25.
984
H1FY23
H2FY23
H1FY24
H2FY24
H1FY25
YTD
FY25 YTD
Trading Update - Australia
7
Australian Testing Business – MetaPanel 500+ sales milestone since launch in March
500+ MetaPanel tests sold since launch
MetaPanel Sales
Australia
350+
365
Surpassed milestone of 500+
tests sold since launch in
March-24
Momentum with ordering
clinicians continues to build
155
H1FY24
H2FY24
H1FY25 YTD
H1FY25
YTD
Continued MetaPanel clinical
adoption growth is expected
to be accelerated by ongoing
sales and marketing activities
as well as upcoming clinical
utility study results and
publications
Trading Update – United Kingdom
8
Advancing next growth phase with MetaXplore access
MetaXplore first sales & samples received and reports delivered in the UK
Advancing into next growth
phase
Appointment of Alaster
Stockwell-Jones as Commercial
Director, Ex Stryker, GE
Healthcare & Eli Lilly
Access to Microba's MetaXplore test has been an eagerly anticipated
milestone by UK practitioners. It's cutting-edge technology and
scientifically graded clinical insights stand to shift the microbiome
testing market here in the UK, and the first experiences with clinicians
positively support this.
Hannah Braye, Clinical Director, Invivo
MetaXplore access commenced
in Oct-24 with first sales,
samples received and reports
delivered.
This focus and investment are
expected to translate into
growth in H2FY25.
Company snapshot
9
Company snapshot
TESTING/
DIAGNOSTICS
THERAPEUTICS
10
Continuous YoY
revenue growth over
6 years of operations
2 diagnostic products opening a
new category with an estimated
US$15B addressable market in
the USA alone
Partnerships with market leaders
incl. Sonic Healthcare (ASX: SHL),
SYNLAB (GR:SYAB) + more
Clinical stage therapeutic
lead candidate advancing to
Phase 2 clinical trial
World-class team
Unequivocal evidence demonstrates that the human gut
microbiome is a critical component of disease
>21,000 Research publications
demonstrate a clear link between chronic
diseases and the gut microbiome1
1 PubMed search terms "gut microbiome/microbiota" or "stool microbiome/microbiota" or "faecal microbiome/microbiota" and "disease"
11
Changing the microbiome can change disease outcomes
>150
Global clinical studies demonstrate that microbiome modulation
can influence disease outcomes and clinical symptoms1
Infectious Disease
Inflammatory Disease
Autoimmune Disease
Cancer
Mental Health
Metabolic Disorders
Heart Disease
Neurodegenerative Disease
1 PubMed search terms "gut microbiome" and "modulate" and "clinical study" and manually selecting for clinical trials with positive results indicated in the abstracts.
12
13
Our diagnostics vision:
To combat disease through microbiome health
14
Our diagnostics focus
Patients suffering from gastrointestinal disease
→
Gastrointestinal
Mental
Cardiovascular
Oncology
Longevity
Fertility
Gastrointestinal Disease
Half of patients are not getting a resolution
37,310,000
Patients presenting annually in the US
with lower GI abdominal symptoms*
21,500,000
Pain, bloating, other
15,370,000
53%
Resolved
15
47%
Unresolved
Diarrhoea
440,000
IBD
% of patients achieving resolution of gastrointestinal
symptoms after 5 years**
* Assessment of Medicare claims analysis. Estimated Private and Medicaid numbers extrapolated from Medicare claims analysis completed with Boston based MedTech specialist consultancy Veranex Inc.
** Gordon, J., Miller, G., & Valenti, L. (2015). The management of unresolved gastrointestinal symptoms in Australian general practice. Australian Family Physician, 44(9), 621-623
***
Addressing the GI symptom challenge
Microba’s comprehensive diagnostic products
First line
Diagnosing
pathogenic causes
of GI symptoms
Gastrointestinal pathogen test
Launched March 2024
Stool DNA test.
175 targets.
Expertly curated clinical recommendations for targeted treatment.
Second line
Identifying functional
causes and treatment
options for
non-pathogenic
GI symptoms
Gastrointestinal disorder test
Launched February 2023
Stool DNA + targeted biomarker test.
7 functional GI markers. >28k microbiome markers.
Expertly curated clinical recommendations for personalised treatment.
16
Getting answers for patients in need
Closing the gap on GI symptom diagnosis and treatment
100%
47%
28% new insights with
*
50%
**
24% new diagnoses with
Unresolved
**
0%
% of patients achieving resolution of
gastrointestinal symptoms after 5 years
52% receiving critical new diagnoses and treatment
recommendation for these patients.
* Study of first 17 months of MetaXplore test results in clinical practice in Australia
** Study of first 4 months of MetaPanel test results in clinical practice in Australia
17
A multi-billion dollar diagnostics market opportunity
$15B+
USA Total Addressable Market*
* Assessment of Medicare claims analysis. Estimated Private and Medicaid numbers extrapolated from Medicare claims analysis completed with Boston based MedTech specialist consultancy Veranex Inc.
Assumes minimum revenue per test of US $416.78 aligned to CPT code 57507. This is viewed to be the minimum with the top pricing predicate at US $2126.20
18
Changing lives every day
“I have struggled with gastrointestinal symptoms for over half my life. I have
tried resolving with many specialists, restrictive eating plans and natural
therapies. My MetaXplore test this year identified clear problems and a
personalised treatment plan. I am grateful that through following the
treatment plan I have achieved complete resolution to my symptoms and
can enjoy eating unrestricted for the first time in 35 years.”
MetaXplore patient,
South Australia
19
20
Our therapeutics vision
To combat disease through microbiome health
20
21
Our primary therapeutic focus
Clinical: Patients suffering from Inflammatory Bowel Disease
Autoimmune
Oncology
Allergy
Neuro
Cardiovascular
→
Gastrointestinal
21
22
Therapeutic Development Programs continue to advance
Core
Program
IBD
(Ulcerative
Colitis)
Discovery
R&D
Undisclosed
(LBP)
Preclinical
Phase 1
Phase 2
•
Inflammatory Bowel Disease Program
- Advancing MAP315 to Phase 2.
•
Immuno-Oncology Program
- Clinical data and sample set grown to
>4,500 patients supporting this
program.
•
Autoimmune Program
- Generated pre-clinical data supporting
lead activity.
MAP 315
(LBP)
Immunooncology
Undisclosed
(LBP)
Autoimmune
Undisclosed
(LBP)
LBP = Live Biotherapeutic Product
22
Recent IBD Transactions
Stage
Upfront
Total Deal
Value
Acquisition
Phase 2
-
US$3.2B
June 2024
License
Preclinical
$150m
US$1.7B
October 2023
Acquisition
Phase 2
-
US$7.2B
October 2023
License
Phase 2b
$500m
US$1.5B
Apr 2023
Acquisition
Phase 2A
-
US$10.8B
Date
Deal Type
July 2024
Licensee /
Acquiror
23
Licensor /
Target
active
complete
active
complete
https://www.reuters.com/markets/deals/eli-lilly-acquire-morphic-holding-32-billion-2024-07-08/ , https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-inks-immune-disorder-drug-licensingdeal-with-chinas-futuregen-2024-06-13/ , https://investor.roivant.com/news-releases/news-release-details/roche-enters-definitive-agreement-acquire-telavant-including , https://www.sanofi.com/en/mediaroom/press-releases/2023/2023-10-04-05-00-00-2754288 , https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/
23
24
Key areas of focus
Financial Snapshot
Diagnostics
Australia - diagnostic sales growth and
clinical adoption
United Kingdom - diagnostic test launch
United States - US reimbursement path
Therapeutics
IBD therapeutic MAP 315 - Phase 2 trial
Therapeutic asset partnering
1 At 27 November 2024 | 2 At 30 June 2024
ASX Code
MAP
Market capitalisation1
$72m
Shares on issue
447.85m
$0.145 / $0.225
52-week low / high1
Cash Balance (30 Sep 2024)
$16.4m
R&D Tax Incentive Refund (Received 15 Nov 24)
$6m
Major Shareholders
Shareholder
Ownership %2
Sonic Healthcare
19.14%
Perennial
14.32%
SA Microba Holdings
7.48%
Thorney Investment Group
6.69%
Macrogen
3.98%
Philip Hugenholtz
3.84%
Gene Tyson
3.82%
JOIN MICROBA’S INTERACTIVE
INVESTOR HUB
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
Visit ir.microba.com/welcome for Microba’s
interactive Investor Hub
CONTACT
Head Office
Level 10, 324 Queen Street
Brisbane QLD Australia
Laboratory
Princess Alexandra Hospital
Woolloongabba QLD Australia
Share your feedback
Discover